Literature DB >> 23239775

Acute liver injury associated with glucosamine dietary supplement.

Vivian Ebrahim1, Mazen Albeldawi, Dian Jung Chiang.   

Abstract

A 55-year-old woman taking  over-the-counter (OTC) glucosamine developed symptomatic hepatotoxicity. Several of her liver enzymes were elevated to 10 times the upper limit of normal. One week after discontinuing glucosamine, serum transaminases fell dramatically, with some returning to normal limits. Four weeks after glucosamine was discontinued, all her liver tests were normal. Rechallenge was not attempted. The potential causes of hepatocellular injury were evaluated. Glucosamine is a dietary supplement available in a wide variety of commercial preparations, primarily used for joint relief in osteoarthritis. Despite the extensive use of glucosamine supplements, significant elevations of transaminases are rare. The mechanism of hepatotoxicity in many OTC herbal preparations is unknown. It is vital for physicians to elicit a careful history of OTC medications and educate their patients on their potential adverse effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23239775      PMCID: PMC4544092          DOI: 10.1136/bcr-2012-007665

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  5 in total

1.  Glucosamine therapy for osteoarthritis: an update.

Authors:  Tanveer E Towheed; Tassos Anastassiades
Journal:  J Rheumatol       Date:  2007-09       Impact factor: 4.666

2.  Acute liver injury associated with the use of herbal preparations containing glucosamine: three case studies.

Authors:  Aileen Smith; John Dillon
Journal:  BMJ Case Rep       Date:  2009-09-02

3.  Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial.

Authors:  Timothy McAlindon; Margaret Formica; Michael LaValley; Melissa Lehmer; Karim Kabbara
Journal:  Am J Med       Date:  2004-11-01       Impact factor: 4.965

4.  Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis.

Authors:  Jolanda Cibere; Jacek A Kopec; Anona Thorne; Joel Singer; Janice Canvin; David B Robinson; Janet Pope; Paul Hong; Eric Grant; John M Esdaile
Journal:  Arthritis Rheum       Date:  2004-10-15

5.  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.

Authors:  Daniel O Clegg; Domenic J Reda; Crystal L Harris; Marguerite A Klein; James R O'Dell; Michele M Hooper; John D Bradley; Clifton O Bingham; Michael H Weisman; Christopher G Jackson; Nancy E Lane; John J Cush; Larry W Moreland; H Ralph Schumacher; Chester V Oddis; Frederick Wolfe; Jerry A Molitor; David E Yocum; Thomas J Schnitzer; Daniel E Furst; Allen D Sawitzke; Helen Shi; Kenneth D Brandt; Roland W Moskowitz; H James Williams
Journal:  N Engl J Med       Date:  2006-02-23       Impact factor: 91.245

  5 in total
  4 in total

1.  Multiorgan dysfunction syndrome secondary to joint supplement overdosage in a dog.

Authors:  Irma J Nobles; Safdar Khan
Journal:  Can Vet J       Date:  2015-04       Impact factor: 1.008

2.  Herbal medicine-related hepatotoxicity.

Authors:  Evangelos Stournaras; Konstantinos Tziomalos
Journal:  World J Hepatol       Date:  2015-09-08

3.  Longitudinal use of complementary and alternative medicine among older adults with radiographic knee osteoarthritis.

Authors:  Shibing Yang; Catherine E Dubé; Charles B Eaton; Timothy E McAlindon; Kate L Lapane
Journal:  Clin Ther       Date:  2013-10-18       Impact factor: 3.393

Review 4.  Glucosamine for osteoarthritis: biological effects, clinical efficacy, and safety on glucose metabolism.

Authors:  Juan Salazar; Luis Bello; Mervin Chávez; Roberto Añez; Joselyn Rojas; Valmore Bermúdez
Journal:  Arthritis       Date:  2014-02-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.